Standout Papers
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease† (2005)
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (2010)
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial (2014)
- Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease (2021)
- Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease (2018)
Immediate Impact
1 by Nobel laureates 7 from Science/Nature 357 standout
Citing Papers
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
2025 Standout
Works of Mark L. Van Natta being referenced
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
2021 Standout
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
2005 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Mark L. Van Natta | 14287 | 733 | 6182 | 5335 | 111 | 18.7k | |
| Cynthia Behling | 12109 | 2 | 5650 | 4666 | 91 | 15.1k | |
| Manal F. Abdelmalek | 12684 | 7 | 5599 | 6079 | 204 | 16.1k | |
| Leon A. Adams | 18336 | 8 | 8886 | 7643 | 198 | 22.2k | |
| Aynur Ünalp–Arida | 9977 | 3 | 4248 | 4092 | 61 | 13.3k | |
| Quentin M. Anstee | 18861 | 17 | 8645 | 7626 | 247 | 22.8k | |
| Geoffrey C. Farrell | 19440 | 8 | 9801 | 6780 | 213 | 25.5k | |
| Michael Charlton | 18908 | 12 | 12598 | 6056 | 247 | 24.5k | |
| Jacob George | 11199 | 14 | 6186 | 3963 | 264 | 14.8k | |
| Valério Nobili | 11262 | 18 | 3611 | 5871 | 283 | 15.5k | |
| Paul Angulo | 21596 | 5 | 11575 | 9010 | 155 | 25.9k |
All Works
Login with ORCID to disown or claim papers
Loading papers...